Endonovo Therapeutics Inc. (ENDV) Promotes Alterna
Post# of 416
(Total Views: 1045)
Posted On: 08/29/2019 3:31:49 PM
Endonovo Therapeutics Inc. (ENDV) Promotes Alternative to Opioid Addiction with Non-Narcotic Wearable Medical Device for Post-Op Pain
- More than 70,000 Americans died from drug overdoses in 2017, marking a two-fold increase over the past decade, and preliminary data shows that another 68,000 overdose deaths occurred in 2018
- Another 40,000 people lost their lives in car crashes in 2018, with drugs such as opioids serving as a contributing factor to impaired driving-related fatalities
- The average rate of later opioid dependence and addiction among surgical patients hovered at 12 percent
- Four out of five heroin users first misused prescription opioids, while 11.5 million people misused opioids in 2016
- Endonovo’s SofPulse(R) is clinically proven to significantly speed recovery following surgery, reducing the need for pain medications that can lead to addiction
- The company’s proprietary wearable device can be used for a wide range of medical conditions and is FDA-cleared for treating post-operative pain and edema in soft tissue
Finding answers to the nation’s opioid epidemic is a complex problem being fought on several fronts. In a news release, Alan Collier, chief executive officer of Endonovo Therapeutics Inc. (OTCQB: ENDV), stated that the company’s SofPulse post-operative opioid alternative medical device delivers clinically-proven post-surgical pain relief to patients.
“With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis,” Collier noted (http://nnw.fm/nwLd6).
Federal statistics show that opioids kill more people per year than car crashes on America’s roadways. An estimated 68,000 Americans died from a drug overdose stemming from opioid abuse in the United States in 2018, although that number could rise once final numbers are compiled, according to Centers for Disease Control and Prevention (CDC) reports (http://nnw.fm/gT4Wv).
The CDC reported that, in 2016, 11.5 million people misused opioids (http://nnw.fm/9We1l), while the Department of Justice reports that four out of five heroin users first misused prescription opioids (http://nnw.fm/OEi2q).
Drug overdose deaths involving any opioid rose from 18,515 deaths in 2007 to 47,600 in 2017, with 68 percent of those deaths occurring among men, per CDC data. In addition, the National Safety Council reports that impaired driving caused by drugs, including opioids, contributed to some of the 40,000 fatal crashes that occurred in each of the past three years (http://nnw.fm/b0PaW).
Endonovo’s SofPulse provides targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue. Endonovo’s SofPulse is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving patients’ natural recovery experiences (http://nnw.fm/O9UUp).
Endonovo’s Electroceutical Therapy(TM) is cleared by the U.S. Food and Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema and is CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.
Dr. Peter Novak, who recently joined Endonovo’s scientific advisory board, said he believes that the company’s noninvasive Electroceutical Therapy represents “a fascinating new frontier.” Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist.
“Endonovo has assembled a pipeline that approaches compelling pathways from unique angles,” Novak stated in a news release (http://nnw.fm/KE4ng). “There is a major need for therapeutics that improve post-operative recuperation, so I am pleased to join a team that has connected novel science with patient need so clearly.”
For more information, visit the company’s website at www.Endonovo.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- More than 70,000 Americans died from drug overdoses in 2017, marking a two-fold increase over the past decade, and preliminary data shows that another 68,000 overdose deaths occurred in 2018
- Another 40,000 people lost their lives in car crashes in 2018, with drugs such as opioids serving as a contributing factor to impaired driving-related fatalities
- The average rate of later opioid dependence and addiction among surgical patients hovered at 12 percent
- Four out of five heroin users first misused prescription opioids, while 11.5 million people misused opioids in 2016
- Endonovo’s SofPulse(R) is clinically proven to significantly speed recovery following surgery, reducing the need for pain medications that can lead to addiction
- The company’s proprietary wearable device can be used for a wide range of medical conditions and is FDA-cleared for treating post-operative pain and edema in soft tissue
Finding answers to the nation’s opioid epidemic is a complex problem being fought on several fronts. In a news release, Alan Collier, chief executive officer of Endonovo Therapeutics Inc. (OTCQB: ENDV), stated that the company’s SofPulse post-operative opioid alternative medical device delivers clinically-proven post-surgical pain relief to patients.
“With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis,” Collier noted (http://nnw.fm/nwLd6).
Federal statistics show that opioids kill more people per year than car crashes on America’s roadways. An estimated 68,000 Americans died from a drug overdose stemming from opioid abuse in the United States in 2018, although that number could rise once final numbers are compiled, according to Centers for Disease Control and Prevention (CDC) reports (http://nnw.fm/gT4Wv).
The CDC reported that, in 2016, 11.5 million people misused opioids (http://nnw.fm/9We1l), while the Department of Justice reports that four out of five heroin users first misused prescription opioids (http://nnw.fm/OEi2q).
Drug overdose deaths involving any opioid rose from 18,515 deaths in 2007 to 47,600 in 2017, with 68 percent of those deaths occurring among men, per CDC data. In addition, the National Safety Council reports that impaired driving caused by drugs, including opioids, contributed to some of the 40,000 fatal crashes that occurred in each of the past three years (http://nnw.fm/b0PaW).
Endonovo’s SofPulse provides targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue. Endonovo’s SofPulse is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving patients’ natural recovery experiences (http://nnw.fm/O9UUp).
Endonovo’s Electroceutical Therapy(TM) is cleared by the U.S. Food and Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema and is CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.
Dr. Peter Novak, who recently joined Endonovo’s scientific advisory board, said he believes that the company’s noninvasive Electroceutical Therapy represents “a fascinating new frontier.” Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist.
“Endonovo has assembled a pipeline that approaches compelling pathways from unique angles,” Novak stated in a news release (http://nnw.fm/KE4ng). “There is a major need for therapeutics that improve post-operative recuperation, so I am pleased to join a team that has connected novel science with patient need so clearly.”
For more information, visit the company’s website at www.Endonovo.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)